KROS
Keros Therapeutics, Inc.Company with tickers: KROS
CIK
1664710
CUSIP
492327101
Shares Outstanding
19,791,837
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $32,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Revenue (ASC 606) | $367,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $26,244,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Research & Development | $16,097,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Operating Income | $-25,877,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Net Income | $-23,708,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Basic) | $-1.21 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Diluted) | $-1.21 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |